Protagonist Therapeutics, Inc.
PTGX
$45.80
-$0.48-1.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 381.70% | 2.62% | 20.40% | 714.80% | 179.94% |
| Total Depreciation and Amortization | -35.58% | -21.77% | 8.65% | -1.44% | -0.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.56% | 27.23% | -1.37% | 18.61% | 14.25% |
| Change in Net Operating Assets | -918.96% | -389.32% | 7,144.00% | -2,950.34% | -471.73% |
| Cash from Operations | -272.04% | -4.70% | 1,123.79% | 20.14% | 153.61% |
| Capital Expenditure | -1,531.58% | -91.83% | 84.09% | -2,320.00% | 72.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 86.27% | -1,480.65% | -439.62% | -35.82% | -1,629.79% |
| Cash from Investing | 85.76% | -1,439.27% | -442.05% | -38.21% | -1,657.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 664.90% | -65.88% | -97.64% | -70.64% | -4.70% |
| Repurchase of Common Stock | -- | -- | 100.00% | -500.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 664.90% | -65.88% | -97.62% | -72.80% | -4.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.67% | -4,524.55% | 69.99% | -829.09% | -61.79% |